It was speculated that the drug may disrupt a pre-existing abnormal endocrine disorder, such as premature activation of the LH receptor, and that cinacalcet may activate both the therapeutic target CaR and the LH receptor simultaneously, thereby inducing hypertestosteronemia and clinical symptoms [41]. This evidence concerns the gene CASR and endocrine system disorder.